Sanjeev Pathak, M.D., is our Senior Vice President, Head of Clinical Development.
Dr. Pathak is a pediatric and adult psychiatrist as well as a clinical neuroscientist with more than 20 years of experience in drug development and clinical research. His experience spans both common and rare diseases including neurodevelopmental, neurodegenerative and neuropsychiatric disorders. He has led or supported teams in achieving approvals for Seroquel® (quetiapine), Seroquel XR® (quetiapine), Aristada® (aripiprazole lauroxil) and LYBALVI® (olanzapine/samidorphan).
Prior to joining Acadia, Dr. Pathak served as Vice President of Clinical Development at Alkermes. Prior to Alkermes, he held roles of increasing responsibility at AstraZeneca and led clinical development efforts across all phases of development. Before transitioning to the industry, he was Assistant Professor of Psychiatry and Pediatrics at University of Cincinnati, College of Medicine.
Over the years, Dr. Pathak has been a practicing physician and brings these lessons to clinical development. He completed his residency and fellowship trainings at University of Cincinnati, College of Medicine Cincinnati Children’s Hospital Medical Center and received his medical training from the top medical school in India, the All-India Institute of Medical Science.
